Shanghai Kaibao Pharmaceutical Market Cap ($746.95 Million)
Market Cap & Net Worth: Shanghai Kaibao Pharmaceutical (300039)
Shanghai Kaibao Pharmaceutical market cap. Shanghai Kaibao Pharmaceutical (SHE:300039) has a market capitalization of $746.95 Million (CN¥5.10 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #9925 globally and #2552 in its home market, demonstrating a 2.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Kaibao Pharmaceutical's stock price CN¥4.88 by its total outstanding shares 1046000000 (1.05 Billion). Also see Shanghai Kaibao Pharmaceutical cash conversion from operations for how efficiently the company converts equity into cash flow.
Shanghai Kaibao Pharmaceutical Market Cap History (2015–2026)
Shanghai Kaibao Pharmaceutical market cap history from 2015 to 2026. Data shows change from $1.45 Billion to $746.95 Million (-5.02% CAGR). Check Shanghai Kaibao Pharmaceutical (300039) share price today for real-time trading data and today's change.
Shanghai Kaibao Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Kaibao Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Shanghai Kaibao Pharmaceutical net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.80x
Shanghai Kaibao Pharmaceutical's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.31x
Shanghai Kaibao Pharmaceutical's market cap is 3.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.08 Billion | $1.50 Billion | $282.61 Million | 0.72x | 3.82x |
| 2017 | $884.38 Million | $1.57 Billion | $272.30 Million | 0.56x | 3.25x |
| 2018 | $572.59 Million | $1.50 Billion | $226.81 Million | 0.38x | 2.52x |
| 2019 | $722.55 Million | $1.42 Billion | $250.99 Million | 0.51x | 2.88x |
| 2020 | $716.10 Million | $908.01 Million | $106.12 Million | 0.79x | 6.75x |
| 2021 | $911.72 Million | $1.10 Billion | $140.11 Million | 0.83x | 6.51x |
| 2022 | $1.20 Billion | $1.12 Billion | $190.80 Million | 1.08x | 6.30x |
| 2023 | $1.00 Billion | $1.59 Billion | $327.87 Million | 0.63x | 3.05x |
| 2024 | $945.93 Million | $1.47 Billion | $375.58 Million | 0.64x | 2.52x |
| 2025 | $922.97 Million | $1.15 Billion | $278.58 Million | 0.80x | 3.31x |
Competitor Companies of 300039 by Market Capitalization
Companies near Shanghai Kaibao Pharmaceutical in the global market cap rankings as of November 5, 2026. Also see 300039 total assets for a full breakdown of the balance sheet.
Key companies related to Shanghai Kaibao Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Shanghai Kaibao Pharmaceutical (2015–2026)
Market capitalization of Shanghai Kaibao Pharmaceutical from 2015 to today. Between 2015 and today, Shanghai Kaibao Pharmaceutical's market cap moved from $1.45 Billion to $ 746.95 Million, with a yearly change of -5.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥746.95 Million | -19.07% |
| 2025 | CN¥922.97 Million | -2.43% |
| 2024 | CN¥945.93 Million | -5.42% |
| 2023 | CN¥1.00 Billion | -16.86% |
| 2022 | CN¥1.20 Billion | +31.94% |
| 2021 | CN¥911.72 Million | +27.32% |
| 2020 | CN¥716.10 Million | -0.89% |
| 2019 | CN¥722.55 Million | +26.19% |
| 2018 | CN¥572.59 Million | -35.26% |
| 2017 | CN¥884.38 Million | -18.08% |
| 2016 | CN¥1.08 Billion | -25.43% |
| 2015 | CN¥1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Shanghai Kaibao Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $746.95 Million USD |
| MoneyControl | $746.95 Million USD |
| MarketWatch | $746.95 Million USD |
| marketcap.company | $746.95 Million USD |
| Reuters | $746.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more